SGLT2 Inhibitor (Innovative NCE)
Type 2 Diabetes Mellitus
Key Facts
About Shenzhen Salubris Pharmaceuticals
Founded in 1998, Shenzhen Salubris Pharmaceuticals has grown from a domestic manufacturer into a Chinese biopharmaceutical leader with a significant public valuation. Its mission centers on addressing critical healthcare needs in chronic diseases through a dual strategy of high-quality generic production and innovative drug development. Key achievements include establishing dominant market positions in cardiovascular and metabolic segments, building a robust pipeline with several late-stage assets, and maintaining consistent profitability to fund R&D. The company's strategy focuses on deepening its therapeutic moats, expanding its innovative portfolio, and navigating the evolving Chinese pharmaceutical reimbursement landscape.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Mellitus Drugs
| Drug | Company | Phase |
|---|---|---|
| Type 2 Diabetes Program | Clinical Research of Philadelphia | Various (Typically Phase 2-4) |
| JTT-662 | Akros Pharma | Phase1 |
| Novel Anti-diabetic Agent (Dual/Triple Agonist) | Shenzhen Salubris Pharmaceuticals | Phase II |
| Metformin HCl API | Vistin Pharma | Commercial |
| Metformin DC Granules | Vistin Pharma | Commercial |